Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

SoFi Technologies’ Stock Remains in Freefall

By Will Ashworth, InvestorPlace Contributor

In my most recent article about SoFi Technologies, I suggested it shouldn’t matter Chamath Palihapitiya sold SOFI stock. Apparently, it does. 

Digital World SPAC Merger Not Worth the Paper It’s Written On

By Will Ashworth, InvestorPlace Contributor

Only the most contrarian investor would consider Digital World Acquisition Corp and Donald Trump’s media empire. Do not buy DWAC stock.

It’s Time to Buy Roku Stock After a 50% Drawdown

By Will Ashworth, InvestorPlace Contributor

If you’re a long-term investor and ROKU stock isn’t on your buy list, you’re missing out on an excellent opportunity to own it. Here’s why.

While Novavax Stock Remains Cursed, It Might Be Time to Buy

By Will Ashworth, InvestorPlace Contributor

Novavax is waiting on good news from the World Health Organization. An EUA would push it above $200. Is it time to buy this cursed stock?  

ContextLogic Is Only a Buy at $2 if Changes Are Made

By Will Ashworth, InvestorPlace Contributor

Since I last wrote about ContextLogic at the end of October, WISH stock has lost 38%. It’s getting closer to my $2 buy recommendation.  

Matterport Stock Chalks up a Big Win With Early Warrant Redemption

By Will Ashworth, InvestorPlace Contributor

Matterport announced it will redeem all outstanding public warrants on Jan. 14. The move adds $79 million in MTTR stock. It's a good thing. 

Not Much News To Justify XYO’s 2021 Value

By Will Ashworth, InvestorPlace Contributor

The XYO token is up more than 600% from XY Labs' Q2 update in June despite the fact that not much has changed to justify the appreciation.

Progenity Is Unlikely to Live Up to Its IPO Hype

By Will Ashworth, InvestorPlace Contributor

Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech?

Christmas Is a Time for Ocugen Shareholders to Give Thanks

By Will Ashworth, InvestorPlace Contributor

This time last year, Ocugen traded below 30 cents. Up 1,683% since, owners of OCGN stock ought to be grateful for their unexpected returns.  

Gores Guggenheim Is a Buy, But Consider an Alternative in the Short Term

By Will Ashworth, InvestorPlace Contributor

Until the Polestar merger with Gores Guggenheim is completed, investors might consider buying Volvo, Geely or CARZ instead of GGPI stock.

Load More